{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:30:09Z","timestamp":1773225009887,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.jaad.2006.06.046","type":"journal-article","created":{"date-parts":[[2006,12,13]],"date-time":"2006-12-13T12:11:16Z","timestamp":1166011876000},"page":"500-505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Acneiform eruptions associated with epidermal growth factor receptor\u2013targeted chemotherapy"],"prefix":"10.1016","volume":"56","author":[{"given":"Christine A.","family":"DeWitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan E.","family":"Siroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen P.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2006.06.046_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jaad.2006.06.046_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/1523-1747.ep12264708","article-title":"Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages","volume":"83","author":"Nanney","year":"1984","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.06.046_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2002.20.1.110","article-title":"Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition","volume":"20","author":"Albanell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.06.046_bib4","first-page":"2478","article-title":"Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients","volume":"9","author":"Malik","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"Suppl 4","key":"10.1016\/j.jaad.2006.06.046_bib5","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0959-8049(01)00233-7","article-title":"The EGFR as a target for anticancer therapy\u2014focus on cetuximab","volume":"37","author":"Baselga","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2006.06.046_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.06.046_bib7","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types","volume":"20","author":"Baselga","year":"2002","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2006.06.046_bib8","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.3816\/CLC.2004.s.010","article-title":"Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer","volume":"6","author":"Perez-Soler","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jaad.2006.06.046_bib9","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2003.10.051","article-title":"Phase II trial of ZD1839 in\u00a0recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"21","author":"Cohen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.06.046_bib10","first-page":"1169","article-title":"Cutaneous side-effects in cancer patients treated with the\u00a0antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br\u00a0J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2006.06.046_bib11","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.06.046_bib12","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2006.06.046_bib13","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non\u2013small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2006.06.046_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-200060001-00002","article-title":"Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy","volume":"60","author":"Raymond","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2006.06.046_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0163-7258(98)00045-X","article-title":"The epidermal growth factor receptor and its inhibition in cancer therapy","volume":"82","author":"Woodburn","year":"1999","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaad.2006.06.046_bib16","unstructured":"Common terminology criteria for adverse events v3.0 (CTCAE). Available at: http:\/\/ctep.cancer.gov\/forms\/CTCAEv3.pdf. Accessed November 30, 2006."},{"issue":"5 Suppl 2","key":"10.1016\/j.jaad.2006.06.046_bib17","first-page":"S98","article-title":"Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?","author":"Saltz","year":"2005","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jaad.2006.06.046_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1101\/gad.8.1.9","article-title":"p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest","volume":"8","author":"Polyak","year":"1994","journal-title":"Genes Dev"},{"key":"10.1016\/j.jaad.2006.06.046_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archderm.138.1.129","article-title":"Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors","volume":"138","author":"Kimyai-Asadi","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.06.046_bib20","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1200\/JCO.2003.04.169","article-title":"Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab","volume":"21","author":"Monti","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.06.046_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/1523-1747.ep12329907","article-title":"Modeling acne in vitro","volume":"106","author":"Guy","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.06.046_bib22","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/1523-1747.ep12343608","article-title":"The improved organ maintenance of\u00a0the human sebaceous gland: modeling in vitro the effects of epidermal growth factor, androgens, estrogens, 13-cis retinoic acid, and phenol red","volume":"106","author":"Guy","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.06.046_bib23","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1006\/exmp.2000.2301","article-title":"Retinoic acid affects the EGF-R signaling pathway during differentiation induction of human endometrial adenocarcinoma cells","volume":"68","author":"Carter","year":"2000","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.jaad.2006.06.046_bib24","first-page":"254","article-title":"Specificity in the synergism between retinoid acid and EGF on the growth of adult human skin fibroblasts","volume":"178","author":"Harper","year":"1988","journal-title":"Exp\u00a0Cell Res"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206040187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206040187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:07:03Z","timestamp":1759270023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962206040187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S0190962206040187"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2006.06.046","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acneiform eruptions associated with epidermal growth factor receptor\u2013targeted chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2006.06.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}